Dexcom Introduces Stelo: First OTC Continuous Glucose Monitor

The device aims to support prediabetes and Type 2 diabetes patients in managing their glucose levels without a prescription.

Stelo is available for $99 per month or $89 with a subscription plan.
FDA approved Stelo in March, making it the first OTC CGM cleared for use.
The monitor transmits glucose data to a smartphone app, providing real-time updates.
Users can log meals, exercise, and other activities to track glucose spikes.
Stelo targets the 125 million Americans with prediabetes or Type 2 diabetes not using insulin.